Trade Mark Journal No.2024/040 4 October 2024

WO0000001808746 (5,44)

Office of origin: United States of America

Date of International Registration:24 May 2024
Date of designation in the UK: 24 May 2024
Image for mark 1808746 BCBIO

International priority date claimed: 1 December 2023 (United States of America) (98293770)
International priority date claimed: 1 December 2023 (United States of America) (98293772)
Class 5
Pharmaceutical and biopharmaceutical products for the prevention and treatment of cancer; pharmaceutical and biopharmaceutical products for immunotherapy; chemical, biochemical, biologic and cell-based preparations for treatment of cancer; biologic and cell-based preparations for immunotherapy; pharmaceutical and biopharmaceutical substances for use in immunotherapy.
Class 44
Medical treatment of cancer; development of personalized medical treatments for individual patients; medical care; genome sequencing for medical purposes; medical analysis services relating to the treatment of persons; cell-based therapy services; immunotherapy services.

BrainChild Bio, Inc.

Representative: Catherine E. Maxson Davis Wright Tremaine LLP, 920 Fifth Avenue, Suite 3300, Seattle WA 98104, UNITED STATES OF AMERICA